NCT02182713
- Conditions
- Asthma, Bronchial Diseases, Hypersensitivity, +6 more
- Locations
-
Not specified
Clinical trial condition
Hypersensitivity, Immediate
Explore clinical trials studying Hypersensitivity, Immediate. Study availability and eligibility vary by location and protocol.
6,724 public trials
629 recruiting studies
Hypersensitivity, Immediate trial results
NCT01340209
- Conditions
- Asthma, Bronchial Diseases, Hypersensitivity, +6 more
- Locations
-
- 205.464.81020 Boehringer Ingelheim Investigational Site Asahikawa, Hokkaido, Japan
- 205.464.81031 Boehringer Ingelheim Investigational Site Atsugi, Kanagawa, Japan
- 205.464.81029 Boehringer Ingelheim Investigational Site Chigasaki, Kanagawa, Japan
- 205.464.81011 Boehringer Ingelheim Investigational Site Chino, Nagano, Japan
NCT00263627
- Conditions
- Hypersensitivity, Hypersensitivity, Immediate, Immune System Diseases, +8 more
- Locations
-
- Allergopharma Joachim Ganzer KG Reinbek, Germany
NCT01611012
- Conditions
- Asthma, Bronchial Diseases, Hypersensitivity, +9 more
- Locations
-
- UMC Utrecht Utrecht, Netherlands
NCT01608243
- Conditions
- Asthma, Bronchial Diseases, Dust Mite Allergy, +13 more
- Locations
-
- CHU Arnaud de Villeneuve Montpellier, France
Completed
The Effect of Aspirin Desensitization on Patients With Aspirin-exacerbated Respiratory Diseases
NCT01867281
- Conditions
- Asthma, Asthma, Aspirin-Induced, Bronchial Diseases, +10 more
- Locations
-
- Department of Allergy and Immunology, Rasool-e-Akram Hospital, Tehran University of Medical Sciences Tehran, Tehran Province, Iran
NCT00928668
- Conditions
- Asthma, Bronchial Diseases, Hypersensitivity, +6 more
- Locations
-
- 1222.4.103 UBC - Respiratory Medicine Vancouver, British Columbia, Canada
- 1222.4.104 Department of Medicine, Health Sciences Centre Hamilton, Ontario, Canada
- 1222.4.101 2725 Chemin Ste Foy Sainte-Foy, Quebec, Canada
- 1222.4.102 Saskatoon, Saskatchewan, Canada
Completed
Regulatory AVAMYS Nasal Spray PMS
NCT01001130
- Conditions
- Hypersensitivity, Hypersensitivity, Immediate, Immune System Diseases, +11 more
- Locations
-
- GSK Investigational Site Seongnam-si Gyeonggi-do, South Korea
Completed
Efficacy and Safety of 4 Weeks of Treatment With Inhaled BI 1744 CL in Patients With Asthma
NCT00467740
- Conditions
- Asthma, Bronchial Diseases, Hypersensitivity, +6 more
- Locations
-
- 1222.6.064 Arthur F. Gelb Medical Corporation, Lakewood Lakewood, California, United States
- 1222.6.062 Boehringer Ingelheim Investigational Site Los Angeles, California, United States
- 1222.6.066 Allergy & Asthma Medical Group and Rsrch Ctr, APC San Diego, California, United States
- 1222.6.069 Allergy Associates Medical Group San Diego, California, United States
NCT01013753
- Conditions
- Asthma, Bronchial Diseases, Hypersensitivity, +6 more
- Locations
-
- 1222.27.43002 Boehringer Ingelheim Investigational Site Linz, Austria
- 1222.27.43004 Boehringer Ingelheim Investigational Site Schlüsslberg, Austria
- 1222.27.43001 Boehringer Ingelheim Investigational Site Thalheim bei Wels, Austria
- 1222.27.43003 Boehringer Ingelheim Investigational Site Vienna, Austria